Lipopeptide for potently inhibiting hiv, derivative thereof, pharmaceutical composition thereof and use thereof

A lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof, characterized in that the lipopeptide is the following a) or b):

• a) a lipopeptide formed by linking a polypeptide having an antiviral activity to a lipophilic compound linked to the carboxyl-terminus of the polypeptide;
• b) a lipopeptide formed by linking a polypeptide having an antiviral activity to a terminal protecting group and a lipophilic compound linked to the carboxyl-terminus of the polypeptide, wherein the terminal protecting group is an amino terminal protecting group and/or a carboxyl terminal protecting group;
• in the a) and b), the polypeptide is any one of P1 to P5:
• the P1 has a sequence as shown in the following Formula I,
• X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23X24X25X26X27X28 Formula I
• in the Formula I,
• X1 to X28 are each an amino acid residue, X1 is W, L or Y, the X2 is E or T, X3 is Q, A or S, X4 is K, N or L, X5 is I or L, X6 is E, D, K, R or A, X7 is E, D, K, R or A, X8 is L or I, X9 is L or I, X10 is K, R, E, D or A, X11 is K, R, E, D or A, X12 is A or S, X13 is E, D, K, R or A, X14 is E, D, K, R or A, X15 is Q, X16 Q, X17 is K, R, E, D or A, X18 is K, R, E, D or A, X19 is N, X20 is E or D, and X21 is E, D, K, R or A, X22 is E, D, K, R or A, X23 is L or I, X24 is K, R, E, D or A, X25 is K, R, E, D or A, X26 is L or I, X27 is E Or D, X28 is K or R;
• the P2 is a polypeptide obtained by deleting 1 to 4 amino acid residues at the amino-terminus of the P1;
• the P3 is a polypeptide obtained by deleting 1 to 3 amino acid residues at the carboxyl-terminus of the P1;
• the P4 is a polypeptide obtained by adding a cysteine residue to the carboxyl-terminus of the P1;
• the P5 has a sequence as shown in the following Formula II,
• X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23X24X25, Formula II
• in the Formula II, the definitions of X5 to X25 are same as those in the Formula I;
• and the polypeptide having an antiviral activity against any one virus selected from the group consisting of the following v1-v7:
• v1:
• HIV-1, HIV-2 and SIV;
• v2:
• HIV-1 and HIV-2;
• v3:
• HIV-1 and SIV;
• v4:
• HIV-2 and SIV;
• v5:
• HIV-1;
• v6:
• HIV-2;
• and
• v7:
• SIV.